Fagan et al1 followed up a group of 61 normal elderly individuals (Clinical Dementia Rating [CDR] 0, ≥60 years old) for a mean time of 3 to 4 years to study cognitive decline. Individuals who progressed during the follow-up from a CDR of 0 to a CDR of 0.5 or higher were defined as converters toward very mild or mild dementia. All the other subjects were considered nonconverters. A cutoff value of 0.214 or greater for the ratio of cerebrospinal fluid (CSF) phosphorylated tau181/β-amyloid42 (ptau181/Aβ42) at baseline was adopted to predict converters and nonconverters at follow-up. The authors' conclusion is that, “CSF tau/Aβ42 ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.”
Vanacore N, Galeotti F, Maggini M, Raschetti R. Biomarkers in Dementia. Arch Neurol. 2007;64(9):1356. doi:10.1001/archneur.64.9.1356
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: